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Abstract The ovary of the desert locust, Schistocerca gregaria,
contains multiple inhibitors of serine proteases. Five serine
protease inhibitors, designated SGPI-1^5 (Schistocerca gregaria
protease inhibitors) were purified from methanolic extracts of
mature ovaries and analyzed by mass spectrometry and amino
acid sequencing. The revealed primary structures display amino
acid similarities and are related to the serine protease inhibitors
identified in the hemolymph of Locusta migratoria. All inhibitors
show an in vitro inhibiting activity towards K-chymotrypsin. In
addition, SGPI-1 displays in vitro inhibiting activity towards
trypsin, and SGPI-2 is a potent pancreatic elastase inhibitor.
Differences in inhibitory specificities towards the locust en-
dogenous serine proteases can be readily attributed to the amino
acid sequence within the active region and also to amino acid
residues beyond the P1-PP1 bond. A difference in one or two
amino acid residues around the reactive sites results in
considerable alteration of the inhibitory specificity. The temporal
and spatial distribution of SGPI-1^5 was studied by RP-HPLC
analysis. All inhibitors occur in hemolymph, ovaries, testes and
fat body of adults but are absent in the gut. They are also present
in larval hemolymph and fat body. An antibody raised against
SGPI-2 shows positive immunostaining in the ovarian follicle
cells.
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1. Introduction
Two di¡erent peptides that inhibit trypsin biosynthesis have
recently been identi¢ed in late vitellogenic ovaries of two car-
nivorous insect species, the mosquito Aedes aegypti and the
gray £esh£y Neobellieria bullata [1,2]. These peptides, which
have no e¡ect on the activity of the enzyme itself, only on its
biosynthesis, are termed trypsin modulating oostatic factors
(TMOF). Peptides displaying such activity have as yet not
been reported in vertebrates. During a search for a peptide
displaying trypsin/chymotrypsin modulating activity in a phy-
tophagous insect, Schistocerca gregaria, we found not only
that such a peptide is present in late vitellogenic ovaries (Jans-
sen et al., unpublished results), but also that the ovary is a
rich source of several classical protease inhibitors that have a
high a⁄nity for the active site of these serine proteases.
Intrigued by this ¢nding, which, in our opinion, might con-
tribute to a better understanding of the complex process of
vitellogenesis and yolk protein degradation during embryo-
genesis, we have undertaken and completed the puri¢cation
of these ovarian serine protease inhibitors. This is the ¢rst
study on protease inhibitors in the ovary of insects. Most of
the serine protease inhibitors in insects examined hitherto
have been identi¢ed or partially characterized from hemo-
lymph extracts and fall into two groups [3] : low molecular
mass proteins (below 10 kDa) related to the Kunitz-type in-
hibitors [4] and proteins of about 45 kDa which belong to the
serpin superfamily [5]. The ¢ve primary structures we present
in this paper di¡er from both the Kunitz-type and the serpin-
type proteinase inhibitors. Together with the three previously
identi¢ed protease inhibitors in the hemolymph of Locusta
migratoria [6^8], they make up a new family of 4 kDa serine
protease inhibitors, stabilized by three disul¢de bridges and
displaying di¡erent enzyme speci¢cities.
2. Materials and methods
2.1. Materials
2.1.1. Insects. Schistocerca gregaria were reared on alfalfa leaves
and bran under a photoperiod of 12 h at a temperature which varied
from 28‡C to 34‡C.
2.1.2. Chemicals. Acetonitrile (CH3CN) of HPLC grade was pur-
chased from Riedel-de Haeºn (Seelze, Germany). Tri£uoroacetic acid
(TFA), methanol, ethylacetate and n-hexane were from Acros Organ-
ics (Geel, Belgium). Dimethylformamide was obtained from Janssen
Chimica. Thyroglobulin, (1-ethyl-3-(dimethylaminopropyl) carbodii-
mide hydrochloride (EDC) and Freund’s adjuvant were from Sigma.
Enzymes (bovine trypsin, bovine chymotrypsin and pancreatic porcine
elastase) and substrates (N-succinyl-Ala-Ala-Ala-p-nitroanilide, N-K-
benzoyl-DL-Arg-p-nitroanilide, N-K-benzoyl-DL-Arg-L-naphthylamide
(BANA), N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide and azocasein)
were also purchased from Sigma.
2.2. Methods
2.2.1. Puri¢cation of the ¢ve serine protease inhibitors from Schisto-
cerca ovary extracts. About 1200 pairs of ovaries from 12^14 day
females were dissected and immediately placed in an ice-cold metha-
nol/water/acetic acid (90:9:1) solution. They were sonicated and cen-
trifuged for 30 min (10 000Ug ; 4‡C). The methanol was evaporated
and the remaining aqueous residue was re-extracted with ethyl acetate
and n-hexane to remove the bulk of lipids. The organic solvent layer
was decanted and the aqueous solution was dried in siliconized round
bottom £asks. Subsequently, it was redissolved in aqueous TFA
(0.1%) and prepuri¢ed on Megabond Elute C18 cartridges (Varian,
Harbor City, CA), which had been activated with CH3CN/H2O/TFA
(80:19.9:0.1) and then rinsed with aqueous 0.1% TFA. The cartridges
were eluted with 25 ml of 50% CH3CN in 0.1% aqueous TFA. Col-
umns and operating conditions for high performance liquid chroma-
tography on a Gilson HPLC system with variable wavelength detector
(214 nm) were: (i) Deltapak C18 column (25U100 mm) (Waters As-
sociates, Milford, MA), solvent A: 0.1% TFA in water; solvent B:
50% CH3CN in 0.1% aqueous TFA. Column conditions: 100% A for
10 min, followed by a linear gradient to 50% B in 80 min; £ow rate:
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6 ml/min; detector range: 2 absorption units full scale (Aufs); (ii)
Deltapak C4 column (7.8U300 mm, 5 Wm) (Waters Associates), sol-
vent A: 0.1% TFA in water; solvent B: 50% CH3CN in 0.1% aqueous
TFA. Column conditions for SGPI-1,2: a linear gradient from 0% B
to 50% B in 70 min; column conditions for SGPI-3,4,5: 0% B for 10
min, then linear gradient to 25% B in 60 min; £ow rate: 1.5 ml/min;
detector range: 2.0 Aufs; (iii) SGPI-1 was puri¢ed to homogeneity on
a Symmetry C18 column (4.6U250 mm) (Waters Associates), solvent
A: 0.1% aqueous TFA; solvent B: 50% CH3CN in 0.1% aqueous
TFA. Column conditions: 100% A for 10 min, followed by a linear
gradient to 50% B in 60 min; £ow rate: 1.5 ml/min; detector range:
0.5 Aufs; (iv) SGPI-2,3,4,5 were further isolated on a Biosep-Sec-S-
2000 column (7.8U300 mm) (Phenomenex, CA), solvent A: 95%
CH3CN in 0.01% aqueous TFA; solvent B: 50% CH3CN in 0.01%
aqueous TFA. Column conditions for SGPI-2,3: 40% B for 10 min,
followed by a linear gradient to 60% B in 60 min; column conditions
for SGPI-4,5: 25% B for 10 min, then a linear gradient to 100% B in
60 min; £ow rate: 1.5 ml/min; detector range: 0.2 Aufs.
Fractions were collected every 2 min for (i) and (ii) and peaks were
collected manually for (iii) and (iv). After each run, aliquots of indi-
vidual fractions (containing about 2 equivalents of ovaries) were
monitored in an enzyme assay to detect chymotrypsin/trypsin inhib-
itory activity.
2.2.2. Mass analyses and amino acid sequence determination. An
aliquot (1.5 Wl) of the ¢nal volume of the pure peak containing pro-
tease inhibiting activity was subjected to MALDI-TOF analysis [9].
Amino acid sequencing was performed on a ABI476A (Applied Bio-
systems, Foster City, CA) or on a Beckman LF 3600 TC protein
sequencer according to Hewick [10].
2.2.3. Measurement of serine protease inhibitory activity. Except
for azocasein, all substrate stock solutions were prepared in dimethyl-
formamide (DMF). HPLC fractions and puri¢ed peptides were
screened for bovine trypsin, chymotrypsin and porcine pancreatic
elastase inhibitory activity as described previously [11]. Inhibitory
activity towards endogenous locust gut proteases was measured as
follows. Mature male insects were starved for 48 h. Then, gut protease
activity was stimulated by a bran diet. After 6 h, the guts were dis-
sected and homogenized in deionized water containing 0.15 M NaCl
and 1 mM CaCl2 (1 gut equivalent per ml). Aliquots of 5 Wl of gut
homogenate were incubated for 45 min in 45 Wl Tris-HCl bu¡er (pH
8.0) with 1.8 nmol each of SGPI-1 and SGPI-2. Control gut homo-
genates were incubated with Tris-HCl bu¡er instead of the Schisto-
cerca protease inhibitors. 20 Wl of each solution was used for native
PAGE electrophoresis according to Laemmli [12] to separate the gut
enzymes. Gut protease bands were revealed by placing the acrylamide
gel bands onto slides with a ¢lm of agar-azocasein gel prepared with
0.2 M Tris-HCl bu¡er (pH 8, 10 mM CaCl2, 1% agar and 0.1%
azocasein). To reveal the site of azocasein degradation, the gel was
stained in a Coomassie blue R250 (0.1%), 25% methanol, 10% acetic
acid solution. Trypsin-like activity was detected by immersing the gel
for 20 min in a solution of 0.2 M Tris-HCl bu¡er (pH 8.0) containing
2 mM BANA, 20 mM NaCl, 2 mM MgCl2 and 0.6% fast black K salt
(Sigma). The gel was washed and ¢xed with 12.5% trichloroacetic
acid.
2.2.4. Antibody production. Two peptides, identical to the N-ter-
minal sequence (EVTCEPGTTFKDKC) and to the C-terminal se-
quence (DGKSAACTLKACPQ) of SGPI-2, were synthesized using
Fmoc polyamide chemistry (J.W. Drijfhout, University Hospital Lei-
den, The Netherlands). Each peptide was then coupled to bovine
thyroglobulin (Sigma) using EDC [13]. Characterization by immu-
no-dot-blot revealed that the SGPI-2 directed antiserum recognized
natural SGPI-2, the synthetic N-terminal and C-terminal peptides of
SGPI-2 (to which it was raised), but not the synthetic N-terminus of
SGPI-3 (CTPGSRKYD).
2.2.5. HPLC analysis of tissue extracts. 200 pmol of the ¢ve na-
tive puri¢ed peptides were injected together on a Gilson HPLC system
(detector set at 214 nm) on a Symmetry C18 column (4.6U250 mm)
(Waters Associates), solvent A: 0.1% aqueous TFA; solvent B: 25%
CH3CN in 0.1% aqueous TFA. Column conditions were: 100% A,
followed by a linear gradient to 100% B in 60 min; £ow rate: 1 ml/
min; detector range: 0.2 Aufs. Extracts of ovaries, testes, hemolymph,
fat body and gut (20 equivalents each) and larval fat body, hemo-
lymph and gut (20 equivalents each) were run under the same con-
ditions. Fractions were collected every minute and assayed for bovine
trypsin and K-chymotrypsin inhibitory activity.
3. Results
3.1. Isolation and identi¢cation of the serine protease inhibitors
from ovary extracts
On the Deltapak C18 preparative column, the inhibitory
activity was separated into four major fractions. These frac-
tions were further puri¢ed so that ¢ve protease inhibitors,
designated SGPI-1^5 (Schistocerca gregaria protease inhibi-
tors 1^5) could be isolated to homogeneity using a three
step HPLC procedure, SGPI-2, 3, 4, and 5 being further iso-
lated on Deltapak C4 and subsequently on Biosep-Sec-S-2000,
and SGPI-1 on Deltapak C4 and on Symmetry C18.
Fig. 1 shows the primary structures of the isolated ovarian
protease inhibitors. All serine protease inhibitors were fully
identi¢ed except SGPI-4, which could only be sequenced up
to Ser35. Due to lack of material, we were unable to perform
an enzymatic digest. For SGPI-1 and SGPI-5, the entire ami-
no acid sequence was obtained in a single sequencing experi-
ment. SGPI-2 could be unequivocally identi¢ed up to amino
acid 34 (Pro). Cloning of the precursor revealed that the ¢nal
amino acid is Gln2 (Vanden Broeck et al., Eur. J. Biochem.,
submitted). The amino acid sequence of SGPI-3 was only
partially obtained by automated Edman degradation. The
C-terminal (Leu-Thr-Phe-Ala) residues were obtained by
cDNA sequencing of the precursor (Vanden Broeck et al.,
Eur. J. Biochem., submitted). The mass spectrometric analysis
of SGPI-3 revealed a molecular mass of 4130. This value
di¡ers by 6 Da from the molecular mass (4136.6 Da) calcu-
lated from the amino acid sequence obtained by Edman deg-
radation. Therefore we conclude that the six cysteine residues
are involved in three disul¢de bridges. Assuming that the six
cysteine residues in SGPI-1 likewise form three disul¢de
bridges, the calculated mass of this peptide corresponds to
the experimentally determined mass (3816 Da).
The molecular mass of SGPI-2 was determined to be 3794
Da from the major peak at 3795.1. Assuming that the six
cysteines form three intramolecular disul¢de bridges, the cal-
culated mass from the amino acid sequence is 3647.8 Da,
which di¡ers by 146 Da from the experimentally determined
mass. Among the posttranslational modi¢cations reported so
far, an O-glycosylation by a deoxyhexose (146 Da) is the most
probable one. This sugar moiety is most likely present on
Thr9 since during Edman cycle 9 an additional unidenti¢ed
peak eluting before the Pth-Thr peak arises, which is absent at
cycle 8 where only a Pth-Thr peak occurs. Assuming three
disul¢de bridges and comparing the calculated (3924 Da)
and the experimental mass (4070 Da), we can deduce that
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Fig. 1. Amino acid sequence of the ¢ve novel serine protease inhibi-
tors of Schistocerca gregaria (SGPI-1^5) and comparison with the
sequences of the serine protease inhibitors of Locusta migratoria
(gaps are introduced to maximize the similarities).
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SGPI-5 is posttranslationally modi¢ed as well. Here also, the
unidenti¢ed peak at cycle 9 of the Edman degradation indi-
cates that the deoxyhexose moiety is present on Thr9.
Since a few C-terminal amino acid residues are missing in
the primary structure of SGPI-4, we cannot calculate the exact
mass. The presence of the above mentioned peak at the Pth-
Thr 10 Edman cycle, which is absent at the Pth-Thr 6 cycle,
suggests that SGPI-4 is also glycosylated. From the experi-
mental mass of 4164 Da we can deduce that no more than
four amino acids at the C-terminal side remain unidenti¢ed.
3.2. Serine protease inhibitory activity
At a concentration of 1 WM, all peptide serine protease
inhibitors inhibit chymotrypsin activity in vitro. Trypsin ac-
tivity is only inhibited by SGPI-1 and elastase activity is in-
hibited by SGPI-2 (Table 1).
The zymogram of the gut homogenate (Fig. 2) reveals nine
bands containing proteolytic activity (lane A1) as demon-
strated with casein as general substrate. One of the four major
protease bands (pb6) contains trypsin-like activity since it was
revealed after incubation with BANA, a substrate for trypsin-
like enzymes (lane B1). SGPI-1 has a large spectrum of inhib-
ition since all bands on the zymogram were abolished in its
presence (lane A2). In the presence of SGPI-2, six out of nine
proteases are inhibited (lane A3). The band containing tryp-
sin-like activity, as revealed with BANA as a substrate (lane
B1), disappears in the presence of SGPI-1 (lane B2) but not in
the presence of SGPI-2 (lane B3), indicating that SGPI-2 dis-
plays no inhibitory activity towards this trypsin-like protease.
3.3. Spatial and temporal distribution of SGPI-1^5
HPLC analysis of di¡erent tissue extracts indicates that all
serine protease inhibitors occur not only in the ovary but also
in testes, hemolymph and fat body (Table 2). They are absent
in the gut. Of particular interest is that a gut speci¢c chymo-
trypsin inhibitor elutes at a retention time of 78 min, which is
much later than all ¢ve ovarian serine protease inhibitors. In
addition, the fat body, hemolymph and testes contain a factor
with chymotrypsin inhibitory activity (elution time 72 min),
which is also absent in the ovary. These inhibitors, which
according to their elution time seem to belong to a di¡erent
family of protease inhibitors, remain to be puri¢ed.
3.4. Immunocytochemical localization of SGPI-1-like
immunoreactivity
In order to demonstrate that the presence of serine protease
inhibitors in the ovary cannot be attributed to the presence of
fat body cells in this organ, we prepared a polyclonal antise-
rum against SGPI-2. By the use of this antiserum, we were
able to demonstrate intense labeling in all the follicle cells
surrounding the maturing eggs (Fig. 3). The labeling is con-
centrated in intensively labeled vesicles, which are more pro-
nounced at the apical side close to the oocyte surface than at
the basal side of the follicle cells.
4. Discussion
All ¢ve ovarian 4 kDa peptides, designated SGPI-1^5, con-
tain six cysteine residues which are involved in three disul¢de
bridges and therefore belong to the same family. Based on the
di¡erence between the calculated mass and the experimental
mass (146 Da), we conclude that SGPI-2, 4 and 5 are post-
translationally modi¢ed by a deoxyhexose moiety. It is the
threonine residue at position 9 or 10 (always on the ¢fth
position after the ¢rst cysteine residue) that is glycosylated.
The deoxyhexose has been identi¢ed as a fucose by Nakakura
et al. [7], who previously identi¢ed two peptides of the same
family in Locusta migratoria. It is as yet unclear why some
serine protease inhibitors contain this sugar while others lack
it. SGPI-3 lacks a threonine at position 9. SGPI-1, however,
has a threonine at position 9, but nevertheless it is not glyco-
sylated.
Fig. 1 shows that SGPI-2 (chymotrypsin inhibitor) displays
a high degree of sequence similarity (83.33%) with the Locusta
protease inhibitor designated PMP-C and LMCI-II by two
research teams who isolated these peptides independently at
the same time [6,7]. Like LMCI-II, SGPI-2 is also a potent
inhibitor of porcine pancreatic elastase. SGPI-2 (35 aa) has
the same structural region containing the presumed active site,
as demonstrated in a detailed kinetic study using synthetic
variants [8]. This sequence similarity is also observed in the
P4 and PP4 residues of the active site region.
SGPI-1 (35 aa) displays a high degree of sequence similarity
(77.14%) with PMP-D2/LMCI-1. However, in contrast to the
Locusta peptide PMP-D2 which was found to interact only
with chymotrypsin and not with trypsin [6,8], SGPI-1 displays
strong in vitro inhibitory activity towards bovine trypsin and
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Fig. 2. Inhibitory activity of SGPI-1 and SGPI-2 on insect gut pro-
teases after PAGE electrophoresis and blotting on agar-casein gel
(A) and on polyacrylamide-BANA gel (B). Gut homogenate (lanes
1), gut homogenate incubated with SGPI-1 (lanes 2), gut homoge-
nate incubated with SGPI-2 (lanes 3).
Table 1
Protease inhibitory activity (%) of the ¢ve serine protease inhibitors (10 WM)
Serine protease (¢nal concentration) SGPI-1 SGPI-2 SGPI-3 SGPI-4 SGPI-5
Bovine trypsin (1.6 WM) 100 0 0 0 0
Bovine K-chymotrypsin (0.08 WM) 100 100 100 100 100
Porcine pancreatic elastase (0.8 WM) 0 100 0 0 0
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much less towards chymotrypsin. In addition, the inhibitory
activity of SGPI-1 towards a locust endogenous trypsin-like
enzyme is in accordance with this e¡ect. The discrepancy is
hard to explain especially when we refer to the work of Kel-
lenberger et al. [8] who located the P1-PP1 active site of PMP-
D2 in the C27TRKGC32 region. SGPI-1 has exactly the same
sequence in exactly the same position. This sequence contains
a Lys and an Arg residue. Many natural trypsin inhibitors
have a Lys as P1 residue and most synthetic substrates for
trypsin have an Arg as P1 residue. Recently, it has been dem-
onstrated that changes of the P1 residue can change not only
the potency of the inhibition, but also the speci¢city [8]. Our
results show that the speci¢city of serine protease inhibitors
may be determined not only by the nature of the P1 residue as
shown by Kellenberger et al. [8], but also by residues beyond
the P1-PP1 bond. In this respect it is noteworthy that the P4
residue is Gly in PMP-D2, whereas it is Ala in SGPI-1. The
PP4 residue is Gln in PMP-D2, whereas it is Pro in SGPI-1.
The P4 residue has been reported to play an important role in
the action of some serine protease inhibitors [14].
Comparing the activity of SGPI-2 and SGPI-4, we reach
the same conclusion. Although SGPI-4 has exactly the same
sequence as SGPI-2 in the reactive site (C28TLKAC33), SGPI-
4 displays no inhibitory activity towards pancreatic elastase,
whereas SGPI-2 is a strong inhibitor of elastase even when
used in lower concentrations. Again, the P4 and PP4 residues
are di¡erent. Previously it has been shown that an alteration
in the PP4 site and even in the PP5 site in a serpin-type pro-
tease inhibitor (i.e. PAI-1 plasminogen activator inhibitor 1)
drastically changes the interaction with the enzyme (tissue-
type plasminogen activator) [15]. A serpin-resistant variant
of the t-PA enzyme is fully inhibited by PAI-1-type molecule
where the P4P site (Glu304) is altered with Arg.
RP-HPLC analysis indicates that the isolated ovarian
SGPIs are also present in the fat body, the hemolymph and
testes but not in the gut. The demonstration of SGPI-2-like
immunoreactivity in the follicle cells surrounding the eggs
(Fig. 3) indicates that the identi¢cation of serine proteases in
the ovary cannot exclusively be attributed to a contamination
of fat body cells or hemolymph. From this study we cannot
conclude whether the ovary is the site of synthesis of some or
of all of the inhibitors. It is possible that some of them are
taken up from the hemolymph. A molecular biological study
on the cloning and expression of some of the inhibitors is
being completed at this moment and will address this question
(Vanden Broeck et al., Eur. J. Biochem., submitted).
In conclusion, the discovery of SGPI-1^5, in addition to HI,
PMP-D2 and PMP-C, indicates the existence of a new family
of serine protease inhibitors which di¡ers from the proteinase
inhibitors of the Kunitz-type family (mass below 10 kDa)
[4,16] and the serpin-type family (mass higher than 45 kDa)
[5]. Based on the high sequence similarities we assume that the
disul¢de pairing is the same in all of the 4 kDa peptide serine
protease inhibitors of this family and that they incorporate a
cysteine knot and a short three-stranded anti-parallel L-sheet
as has been described for PMP-D2 and PMP-C [17^19]. Point
amino acid changes in and around the active site are able to
change the potency and speci¢city of the inhibitors. Also to-
wards the insect endogenous serine proteases, they display
di¡erent speci¢cities as shown by our electrophoresis study.
This suggests that they might play a complementary role in
the ¢netuning of the proteases that are implicated in the di-
verse physiological processes during insect development (molt,
immune system, digestion, ovarian development, digestion of
yolk proteins, protection against parasites) [20^22].
FEBS 19733 26-1-98
Table 2
Tissue distribution of serine protease inhibitory activity as revealed by RP-HPLC analysis on a C18 column
Inhibitor SGPI-1 SGPI-2 SGPI-3 SGPI-4 SGPI-5
Elution time 24 min 42 min 48 min 52 min 56 min 72 min 78 min
Mass (Da) 3816 3794 4130 4164 4070 unknown unknown
Vitellogenic ovary + + + + + 3 3
Adult fat body + + + + + + 3
Adult hemolymph + + + + + + 3
Adult gut 3 3 3 3 3 3 +
Adult testes 3 + + + + + 3
Larval hemolymph + + + + + + 3
Larval fat body + + + + + + 3
Larval gut 3 3 3 3 3 3 3
Fig. 3. Cross-sections of ovariole of Schistocerca gregaria (a: U175,
b: U420). SGPI-2-like immunoreactive vesicles (arrows) are present
in the follicle cells, surrounding the oocyte.
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